Business Wire

Effective June 10, Dr. Richard will foster connectivity, alignment and innovation in operations at City of Hope National Medical Center, City of Hope Los Angeles, City of Hope Orange County and City of Hope’s Southern California clinical network

LOS ANGELES--(BUSINESS WIRE)-- City of Hope®, one of the largest cancer research and treatment organizations in the United States, today announced that effective June 10, Angelique L. Richard, Ph.D., R.N., will be... (continue reading...)

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- At ASMS 2024, SCIEX, a global leader in life science analytical technologies, introduces ZT Scan DIA for LC-MS/MS, the next generation in data-independent acquisition (DIA) that leverages the combination of the quadrupole dimension with the rich MS2 data attainable from the Zeno trap.

DIA allows for the measurement of all compounds within a sample in a targeted manner. It has been a central catalyst for shifting mass... (continue reading...)

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- At ASMS 2024, SCIEX, a global leader in life science analytical technologies, launches the SCIEX 7500+ system, the newest mass spectrometer in the SCIEX quantitative portfolio, building upon a legacy of reliable, sensitive quantitation. While sensitivity is critical to solve the most impactful analytical challenges, scientists are under pressure to meet deadlines faster and to quantify from increasingly various and complex sample... (continue reading...)

WASHINGTON--(BUSINESS WIRE)-- Capital Edge Consulting, the nation’s leading independent U.S. government contract consulting firm, is excited to announce that Tony Worick has joined the firm as Partner.

Based in the National Capital Region, Tony brings nearly twenty years of expertise in all facets of government contracting, having supported a large variety of both major and mid-size government contractors. Tony has earned the reputation as a government contracts... (continue reading...)

LONDON--(BUSINESS WIRE)-- Today, invoX Pharma Limited (“invoX”), a research-driven global biopharmaceutical company with an advancing pipeline of innovative products, has presented updated findings from its ongoing phase 1 study of FS222, an investigational CD137/PD-L1 bispecific antibody, in patients with advanced solid tumours. These data demonstrated encouraging anti-tumour activity in multiple tumour types with a manageable safety profile. These preliminary... (continue reading...)